SCHEMBL17045862

SCHEMBL17045862

CNC(=O)c1cccc(SCCCCCC(=O)Nc2ccccc2O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
RAB9A P51151 2/20 0.56
HDAC3 O15379 9/20 0.49
HDAC1 Q13547 7/20 0.49
HDAC4 P56524 2/20 0.45
HDAC7 Q8WUI4 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC10 Q969S8 2/20 0.45
HDAC11 Q96DB2 2/20 0.45
HDAC8 Q9BY41 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45
HDAC9 Q9UKV0 2/20 0.45
HDAC5 Q9UQL6 2/20 0.45
IL15 P40933 1/20 0.45
IL15RA Q13261 1/20 0.45
TDP1 Q9NUW8 1/20 0.43
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31734067 1.00 MEN1 (0.56) MEN1KMT2ARAB9AHDAC3HDAC1
SCHEMBL17045852 0.88 HDAC3 (0.58) HDAC3HDAC1HDAC4HDAC7HDAC2
SCHEMBL17056832 0.88 RAB9A (0.65) MEN1KMT2ARAB9AHDAC3HDAC1
SCHEMBL31734079 0.88 RAB9A (0.65) MEN1KMT2ARAB9AHDAC3HDAC1
SCHEMBL15694844 0.83 RAB9A (0.74) MEN1KMT2ARAB9AHDAC3HDAC1
SCHEMBL20545465 0.82 MEN1 (0.60) MEN1KMT2ARAB9AHDAC3HDAC1
SCHEMBL20544908 0.82 MEN1 (0.70) MEN1KMT2ARAB9AHDAC3HDAC1
SCHEMBL20545190 0.82 MEN1 (0.57) MEN1KMT2ARAB9AHDAC3HDAC1
SCHEMBL17045911 0.81 ALDH1A1 (0.51) MEN1KMT2ARAB9AHDAC3HDAC1
SCHEMBL17045878 0.79 MEN1 (0.53) MEN1KMT2ARAB9AHDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12478594-B2 Methods of treatment of kidney injury associated with infection or trauma University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-11-25 US disclosed
US-20220226266-A1 Methods of Treatment of Kidney Injury Associated with Infection or Trauma NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-07-21 US disclosed
WO-2020240524-A2 METHODS OF TREATMENT OF KIDNEY INJURY ASSOCIATED WITH INFECTION OR TRAUMA UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2020-12-03 WO disclosed
US-10233201-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburg—Of the Commonwealth System of Higher Education (US) 2019-03-19 US disclosed
US-20170320898-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2017-11-09 US disclosed
US-9670236-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2017-06-06 US disclosed
US-9670236-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2017-06-06 US disclosed
US-20150246939-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2015-09-03 US disclosed
US-20150246939-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2015-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10233201-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury HDAC1, HDAC9, HDAC11 MEN1 4549/4885KMT2A 41/4885RAB9A 1305/4885
US-20220226266-A1 Methods of Treatment of Kidney Injury Associated with Infection or Trauma MMP8, PLAU, KLKB1 MEN1 3286/4885KMT2A 3363/4885RAB9A 2356/4885
US-20150246939-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury HDAC1, HDAC9, HDAC11 MEN1 4549/4885KMT2A 41/4885RAB9A 1305/4885
US-12478594-B2 Methods of treatment of kidney injury associated with infection or trauma HDAC1, HDAC2, HDAC4 MEN1 4252/4885KMT2A 51/4885RAB9A 3691/4885
US-20170320898-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury HDAC1, HDAC9, HDAC11 MEN1 4549/4885KMT2A 41/4885RAB9A 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.